论文部分内容阅读
目的探讨CEA多肽负载的自体树突状细胞(DC)治疗晚期肺癌的安全性和近期疗效。方法分离患者外周血单核细胞,用重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)和白介素-4(rhIL-4)体外诱导DC,CEA多肽负载自体DC,对8例HLA-A2阳性且CEA较高的晚期肺癌患者进行4次DC免疫治疗,观察其安全性、免疫功能和临床疗效。结果治疗中未出现明显不良反应,血清中IL-2、IL-12、IFN-γ和TNF-α水平治疗后呈明显上升趋势,4例患者的DTH检测阳性;4例患者血清CEA降低,2例平稳,2例升高。7例有可评价病灶的患者中,1例部分缓解(PR)、1例轻微缓解(MR)、3例稳定(SD)、2例进展(PD)。结论CEA负载的自体DC治疗晚期肺癌患者可改善患者的免疫功能,激发特异性免疫反应,缓解病情,且不良反应少,为肺癌的免疫治疗提供了一条新途径。
Objective To investigate the safety and short-term efficacy of CEA polypeptide-loaded autologous dendritic cells (DCs) in the treatment of advanced lung cancer. Methods Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood mononuclear cells (DCs) and DCs were induced by recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and interleukin-4 (rhIL- A2 positive and advanced CEA patients with advanced lung cancer for 4 times DC immunotherapy to observe its safety, immune function and clinical efficacy. Results No significant adverse reactions were observed in the treatment. Serum levels of IL-2, IL-12, IFN-γ and TNF-α were significantly increased after treatment. DTH test was positive in 4 patients. Serum CEA was decreased in 4 patients, 2 A stable case, 2 cases increased. Among the 7 patients with evaluable lesions, 1 was partly relieved (PR), 1 was slightly relieved (MR), 3 was stable (SD) and 2 was progressing (PD). CONCLUSION: CEA-loaded autologous DC can improve immune function, stimulate specific immune response and relieve the disease in patients with advanced lung cancer, and provide fewer adverse reactions. It provides a new approach for immunotherapy of lung cancer.